
MBX Stock Forecast & Price Target
MBX Analyst Ratings
Bulls say
MBX Biosciences Inc. has demonstrated a significant clinical advancement with canvuparatide, highlighted by a 63% composite response at 12 weeks and a 69% response in both the 600 ug and 800 ug dosage groups, which surpassed expectations from both analysts and Key Opinion Leaders (KOLs). Additionally, strong patient engagement is evident, with 94% of subjects entering the open-label extension phase, signaling considerable enthusiasm and the potential for improved long-term efficacy. Furthermore, the promising safety profile of canvuparatide is underscored by minimal adverse events, along with supportive market research indicating a positive outlook for the drug's commercial viability in addressing endocrine disorders.
Bears say
MBX Biosciences Inc. faces significant downside risks that could negatively impact its financial performance and stock outlook. Specifically, there are concerns regarding the efficacy and safety outcomes of their Phase 2 and Phase 3 clinical trials for chronic hypoparathyroidism, coupled with the potential for unforeseen delays in research and development activities. Additionally, the company may encounter competitive pressures from new market entrants and existing therapies that outperform its product candidates, further exacerbating its financial challenges.
This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
MBX Analyst Forecast & Price Prediction
Start investing in MBX
Order type
Buy in
Order amount
Est. shares
0 shares